Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality? (Q26776338)

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Long-term follow-up of patients with NAFLD and elevated liver enzymes

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Relationship of hepatitis C virus infection with diabetes in the U.S. population

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

The relationship between hepatitis C virus infection and diabetes: time for a divorce?

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Insulin sensitivity, insulin secretion and glucose effectiveness in diabetic and non-diabetic cirrhotic patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Chronic HCV infection is a risk factor of ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

HCV and diabetes. A two-question-based reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Hepatitis C virus infection in a population with high incidence of type 2 diabetes: impact on diabetes complications

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

The metabolic syndrome--a new worldwide definition

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Fibrogenic impact of high serum glucose in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

The interaction of metabolic factors with HCV infection: does it matter?

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Host- and disease-specific factors affecting steatosis in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Clinical implications of hepatogenous diabetes in liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Hepatitis C virus infection and incident type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

A role for hepatitis C virus infection in type II cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Membranoproliferative glomerulonephritis associated with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Association of serum adipocytokines with insulin resistance and liver injury in patients with chronic hepatitis C genotype 4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Hepatitis C and steatosis: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Eradication of hepatitis C virus by interferon improves whole-body insulin resistance and hyperinsulinaemia in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

HCV and diabetes mellitus: evidence for a negative association

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Hepatitis C virus dysregulates glucose homeostasis by a dual mechanism involving induction of PGC1α and dephosphorylation of FoxO1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Association between IL28B polymorphism, TNFα and biomarkers of insulin resistance in chronic hepatitis C-related insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Insulin resistance and hepatitis C: an evolving story

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Cardiovascular diseases and HCV infection: a simple association or more?

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Methods of accelerated atherosclerosis in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Evaluation of endothelial function and subclinical atherosclerosis in association with hepatitis C virus in HIV-infected patients: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

SOCS3 and IRS-1 gene expression differs between genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Metabolic alterations and chronic hepatitis C: treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Current understanding of insulin resistance in hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

The predictive value of steatosis in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Hepatitis C and diabetes: the inevitable coincidence?

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Iron involvement in multiple signaling pathways of atherosclerosis: a revisited hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Prevalence of diabetes and incidence of angiopathy in patients with chronic viral liver disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Insulin resistance, adipokine profile and hepatic expression of SOCS-3 gene in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Adiponectin serum level in chronic hepatitis C infection and therapeutic profile

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.10.016

7 January 2021